Rekvina Laboratories Limited (BOM:526075)

Rekvina Laboratories Income Statement

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Revenue	19.34	12.65	-	-	-	-
Revenue Growth	-	-	-	-	-	-
Cost of Revenue	18.38	11.82	-	-	-	-
Gross Profit	0.96	0.84	-	-	-	-
Selling, General & Admin	2.47	2.3	0.45	-	-	-
Other Operating Expenses	1.89	1.09	0.93	0.16	0.04	0.75
Operating Expenses	4.36	3.39	1.37	0.16	0.04	0.75
Operating Income	-3.4	-2.55	-1.37	-0.16	-0.04	-0.75
Other Non Operating Income (Expenses)	-	-	-	-	-0	-0.03
EBT Excluding Unusual Items	-3.4	-2.55	-1.37	-0.16	-0.05	-0.79
Other Unusual Items	-	-	-	-	0.04	-
Pretax Income	-3.4	-2.55	-1.37	-0.16	-0.01	-0.79
Net Income	-3.4	-2.55	-1.37	-0.16	-0.01	-0.79
Net Income to Common	-3.4	-2.55	-1.37	-0.16	-0.01	-0.79
Net Income Growth	-	-	-	-	-	-
Shares Outstanding (Basic)	6	6	6	6	6	6
Shares Outstanding (Diluted)	6	6	6	6	6	6
Shares Change	-	0.60%	-	-	-0.66%	-
EPS (Basic)	-0.56	-0.42	-0.23	-0.03	-0.00	-0.13
EPS (Diluted)	-0.56	-0.42	-0.23	-0.03	-0.00	-0.13
EPS Growth	-	-	-	-	-	-

Additional Metrics

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Gross Margin	4.98%	6.62%	-	-	-	-
Operating Margin	-17.57%	-20.13%	-	-	-	-
Profit Margin	-17.57%	-20.13%	-	-	-	-
EBIT	-3.4	-2.55	-1.37	-0.16	-0.04	-0.75
EBIT Margin	-17.57%	-20.13%	-	-	-	-
Revenue as Reported	19.34	12.65	-	-	0.04	-
Advertising Expenses	-	-	0.02	-	-	-

Data Source: S&P Global Market Intelligence Last updated: Jun 30, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Sep 3, 2026

Data Sources Report a data error